Abstract: Periosteum harvesting and processing systems and methods enable rapid, efficient, and repeatable harvesting of periosteum tissue from human long bones and processing of the tissue into individual fibers for use in strengthening surgical allograft products. One harvesting and processing method involves providing a human long bone, securing the long bone between two rotating live centers, scraping, using one of a plurality of harvesting tools selected from a harvesting and processing kit, periosteum tissue from the long bone, executing a first wash cycle comprising a hydrogen peroxide wash, executing a second wash cycle comprising an isopropyl alcohol wash, executing a third wash cycle comprising a phosphate buffered saline wash, compressing the periosteum tissue to remove excess fluid, cryofracturing the tissue until a desired fiber size is achieved, and separating the periosteum tissue into individual periosteum fibers having the desired fiber size. Other embodiments are also disclosed.

Abstract: Periosteum harvesting and processing systems and methods enable rapid, efficient, and repeatable harvesting of periosteum tissue from human long bones and processing of the tissue into individual fibers for use in strengthening surgical allograft products. One harvesting and processing method involves providing a human long bone, securing the long bone between two rotating live centers, scraping, using one of a plurality of harvesting tools selected from a harvesting and processing kit, periosteum tissue from the long bone, executing a first wash cycle comprising a hydrogen peroxide wash, executing a second wash cycle comprising an isopropyl alcohol wash, executing a third wash cycle comprising a phosphate buffered saline wash, compressing the periosteum tissue to remove excess fluid, cryofracturing the tissue until a desired fiber size is achieved, and separating the periosteum tissue into individual periosteum fibers having the desired fiber size. Other embodiments are also disclosed.

Abstract: Provided are systems and methods for treating or processing tissue, and tissue products made using such systems and methods. The methods involve combining tissue with a processing solution in a processing vessel and applying resonant acoustic energy thereto. In some instances, the tissue is processed in the absence of processing solution. The resonant acoustic energy rapidly agitates the tissue with the processing solution by vibration. The general method provided is broadly applicable to a variety of tissue processing methods, the processing solution and features of the resonant acoustic energy being selected based on the type of tissue to be processed and the nature of the processing to be performed. Exemplary methods include methods of bone demineralization, tissue decellularization, tissue cryopreservation, production of stromal vascular fraction, tissue homogenization, tissue cleansing, and tissue decontamination, and assessment of microbial load.

Abstract: Embodiments of this technology may include an apparatus for drying tissue. The apparatus may include human donor tissue placed in contact with and between at least two layers of backing material. This tissue and backing layer may then be restrained by two plates. This tissue may be amniotic tissue. The backing layer may include woven or nonwoven material. This backing layer may be wetted with a saline solution. At least one of the plates of the tissue drying apparatus may be perforated. The tissue assembly along with the plates may then be placed inside a chamber configured to receive the plates and tissue assembly. The chamber may be configured so that gas can be forced into the chamber with the gas flow going around the plates and the tissue assembly.

Abstract: Embodiments of the present technology may permit for native, intact, natural, human-derived, or allograft-derived fibers to be used as threads for suturing. Embodiments may include a thread for suturing. The thread may include a first portion, which includes a fascia fiber. The first portion may have a first end that includes the fascia fiber. The thread may also include a second portion including a non-human-derived fiber. The second portion may have a first end that includes the non-human-derived fiber. The first end of the second portion may be attached to the first end of the first portion. Embodiments may include a method of forming a thread. The method may include attaching a first end of a fascia fiber to a first end of a first non-human-derived fiber. The method may also include attaching a second end of the fascia fiber to a first end of a second non-human-derived fiber.

Abstract: Embodiments of the present technology include a method of making a bone composite graft for administration to a patient. The method may include combining a human cadaveric bone material with a plurality of polymethyl methacrylate binder particles and spincasting the combined human cadaveric bone material and polymethyl methacrylate binder particles to produce the bone composite graft. The method may also include ablating the bone composite graft to increase the surface area of bone material exposed. The human cadaveric bone material may be immobilized in the plurality of polymethyl methacrylate binder particles. The human cadaveric bone material may be present in an amount that is 50 weight percent of the bone composite graft, or less. Additionally, the bone composite graft may have a yield strength that is at least 13,000 N/cm2 and no greater than 15,000 N/cm2.

Abstract: Periosteum harvesting and processing systems and methods enable rapid, efficient, and repeatable harvesting of periosteum tissue from human long bones and processing of the tissue into individual fibers for use in strengthening surgical allograft products. One harvesting and processing method involves providing a human long bone, securing the long bone between two rotating live centers, scraping, using one of a plurality of harvesting tools selected from a harvesting and processing kit, periosteum tissue from the long bone, executing a first wash cycle comprising a hydrogen peroxide wash, executing a second wash cycle comprising an isopropyl alcohol wash, executing a third wash cycle comprising a phosphate buffered saline wash, compressing the periosteum tissue to remove excess fluid, cryofracturing the tissue until a desired fiber size is achieved, and separating the periosteum tissue into individual periosteum fibers having the desired fiber size. Other embodiments are also disclosed.

Abstract: Composite grafts including a biocompatible, synthetic scaffold; and a biological tissue component obtained or derived from a deceased donor tissue, wherein the biological tissue component is embedded in the biocompatible, synthetic scaffold, are provided as systems relating thereto. Methods of manufacture and methods of treatment using such grafts are also provided.

Abstract: There is disclosed a customizable system and methods of use for manufacturing and testing a variety of pre-sutured allograft tendon constructs sutured according to a variety of stitching patterns and featuring a variety of tissue lengths and types. One embodiment includes a triple-channel base having first, second, and third longitudinal channels extending between first and second ends of the base, as well as a plurality of tendon-manipulation accessories. Each of the tendon-manipulation accessories includes a locking-base assembly for selectively securing the accessory to the base such that the multiple tendon-manipulation accessories may be secured to the triple-channel base in a variety of custom arrangements suitable for preparing the variety of pre-sutured constructs and/or for pre-tensioning or testing the variety of the pre-sutured constructs. Other embodiments are also disclosed.

Abstract: Provided in this disclosure are various composite grafts having a trabecular scaffold with voids defined in at least a portion of the scaffold and a biological component positioned in at least some of the voids of the scaffold. The grafts may have a synthetic scaffold or a bone substrate scaffold. The grafts may be osteogenic, chondrogenic, osteochondrogenic, or vulnerary in nature. Also provided are methods of using the composite grafts to treat a tissue defect in a subject. Methods of manufacturing are also provided. Synthetic scaffolds are manufactured by additive manufacturing. Agitation is used to combine the biological component with the scaffold of the graft.

Abstract: Provided in this disclosure are various composite grafts having a trabecular synthetic scaffold with voids defined in at least a portion of the scaffold and a biological component positioned in at least some of the voids of the scaffold. The grafts may be osteogenic, chondrogenic, osteochondrogenic, or vulnerary in nature. Also provided are methods of using the composite grafts to treat a tissue defect in a subject. Methods of manufacturing are also provided. Grafts are manufactured by additive manufacturing. Agitation may be used to combine composite grafts with additional biological component.

Abstract: Provided are systems and methods for treating or processing tissue, and tissue products made using such systems and methods. Also provided are ball mill processing devices and systems useful for processing materials such as tissue. The methods involve combining tissue with or without a processing solution in a processing vessel and applying resonant acoustic energy thereto. The resonant acoustic energy rapidly agitates the tissue with the processing solution by vibration, thereby improving the rate and/or efficiency of processing. The general method provided is broadly applicable to a variety of tissue processing methods, the processing solution and features of the resonant acoustic energy being selected based on the type of tissue to be processed and the nature of the processing to be performed.

Abstract: Embodiments of the present technology may permit for native, intact, natural, human-derived, or allograft-derived fibers to be used as threads for suturing. Embodiments may include a thread for suturing. The thread may include a first portion, which includes a fascia fiber. The first portion may have a first end that includes the fascia fiber. The thread may also include a second portion including a non-human-derived fiber. The second portion may have a first end that includes the non-human-derived fiber. The first end of the second portion may be attached to the first end of the first portion. Embodiments may include a method of forming a thread. The method may include attaching a first end of a fascia fiber to a first end of a first non-human-derived fiber. The method may also include attaching a second end of the fascia fiber to a first end of a second non-human-derived fiber.

Abstract: Embodiments of this technology may include an apparatus for drying tissue. The apparatus may include human donor tissue placed in contact with and between at least two layers of backing material. This tissue and backing layer may then be restrained by two plates. This tissue may be amniotic tissue. The backing layer may include woven or nonwoven material. This backing layer may be wetted with a saline solution. At least one of the plates of the tissue drying apparatus may be perforated. The tissue assembly along with the plates may then be placed inside a chamber configured to receive the plates and tissue assembly. The chamber may be configured so that gas can be forced into the chamber with the gas flow going around the plates and the tissue assembly.

Abstract: Embodiments of the present technology include a graft for administration at a treatment site of a patient. The graft may include a human cadaveric bone material bonded together with a polymeric binder. The human cadaveric bone material may include demineralized bone particles. The demineralized bone particles may have an average diameter less than 1.1 mm, less than 750 ?m, less than 500 ?m, or less than 250 ?m. The human cadaveric bone material may include non-demineralized bone, cancellous bone, and/or cortical bone in embodiments. In some embodiments, bone from animals other than humans may be used, and the patient may be an animal other than a human.

Abstract: Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.

Abstract: Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.

Abstract: Embodiments of the technology may involve a method of processing the human donor tissue for administration to a recipient. This method may include the step of contacting the human donor tissue with a backing layer, where the human donor tissue and the backing layer contain a saline solution. This saline solution may include a solvent and a disassociated salt. The method may further include evaporating a portion of the solvent from a surface of the backing layer. The evaporation of the solvent may move a portion of the disassociated salt from the donor tissue to the backing layer. This process may then result in a tissue that is mostly dry and free of salt crystals.

Abstract: Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.

Abstract: Embodiments of the present technology include a graft for administration at a treatment site of a patient. The graft may include a human cadaveric bone material bonded together with a polymeric binder. The human cadaveric bone material may include demineralized bone particles. The demineralized bone particles may have an average diameter less than 1.1 mm, less than 750 ?m, less than 500 ?m, or less than 250 ?m. The human cadaveric bone material may include non-demineralized bone, cancellous bone, and/or cortical bone in embodiments. In some embodiments, bone from animals other than humans may be used, and the patient may be an animal other than a human.